📣 VC round data is live. Check it out!

Kinaxis Valuation Multiples

Discover Kinaxis' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Wuchan Zhongda Group Co, Xiamen Xiangyu Co, SPS Commerce, HopeRun and more.

Kinaxis Overview

About Kinaxis

Kinaxis Inc is a provider of cloud-based subscription software that enables its customers to improve and accelerate analysis and decision-making across their supply chain operations. The company has operations in the United States, Japan, Hong Kong, The Netherlands, South Korea, the United Kingdom, Romania, Mexico, Singapore, France, Ireland, Germany, India, and Canada. , and a majority of the revenue comes from the United States.


Founded

2013

HQ

Canada

Employees

1.7K

Financials (LTM)

Revenue: $585M
EBITDA: $150M

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Kinaxis Financials

Kinaxis reported last 12-month revenue of $585M and EBITDA of $150M.

In the same LTM period, Kinaxis generated $383M in gross profit, $150M in EBITDA, and $75M in net income.

Revenue (LTM)


Kinaxis P&L

In the most recent fiscal year, Kinaxis reported revenue of $548M and EBITDA of $138M.

Kinaxis is profitable as of last fiscal year, with gross margin of 65%, EBITDA margin of 25%, and net margin of 13%.

See analyst estimates for Kinaxis
LTMLast FY202320242025202620272028
Revenue$585M$548M$427M$483M$548M
Gross Profit$383M$354M$259M$295M$354M
Gross Margin66%65%61%61%65%
EBITDA$150M$138M$40M$38M$99M
EBITDA Margin26%25%9%8%18%
EBIT Margin16%15%3%3%15%
Net Profit$75M$71M$10M$56K$71M
Net Margin13%13%2%0%13%

Financial data powered by Morningstar, Inc.

Kinaxis Stock Performance

Kinaxis has current market cap of $3B, and enterprise value of $3B.

Market Cap Evolution


Kinaxis' stock price is $122.93.

Kinaxis share price increased by 8.1% in the last 30 days, and decreased by 16.9% in the last year.

Kinaxis has an EPS (earnings per share) of $2.59.

See more trading valuation data for Kinaxis
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$3B-0.4%8.1%20.2%-16.9%$2.59

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Kinaxis Valuation Multiples

Kinaxis trades at 5.3x EV/Revenue multiple, and 20.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Kinaxis

EV / Revenue (LTM)


Kinaxis Financial Valuation Multiples

As of June 3, 2026, Kinaxis has market cap of $3B and EV of $3B.

Kinaxis has a P/E ratio of 45.0x.

LTMLast FY202320242025202620272028
EV/Revenue5.3x5.6x7.2x6.4x5.6x
EV/EBITDA20.5x22.2x76.2x81.7x31.0x
EV/EBIT33.3x38.7x218.3x241.7x38.7x
EV/Gross Profit8.0x8.7x11.9x10.5x8.7x
P/E45.0x47.5xn/mn/m47.5x
EV/FCF25.9x27.5x40.0x32.5x27.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Kinaxis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Kinaxis Margins & Growth Rates

Kinaxis grew revenue by 16% and EBITDA by 20% in the last fiscal year.

In the most recent fiscal year, Kinaxis reported gross margin of 65%, EBITDA margin of 25%, and net margin of 13%.

See estimated margins and future growth rates for Kinaxis

Kinaxis Margins

Last FY202420252026202720282029
Gross Margin65%61%65%67%
EBITDA Margin25%8%18%26%
EBIT Margin15%3%15%17%
Net Margin13%0%13%13%
FCF Margin20%20%20%20%

Kinaxis Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth16%13%13%16%
Gross Profit Growth19%14%20%19%
EBITDA Growth20%(7%)164%68%
EBIT Growth39%(10%)524%39%
Net Profit Growth13%(99%)126148%13%
FCF Growth14%23%18%14%

Data powered by FactSet, Inc. and Morningstar, Inc.

Kinaxis Operational KPIs

Kinaxis' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Kinaxis' Rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Kinaxis' Rule of X is 66% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Kinaxis
LTMLast FY202320242025202620272028
Rule of 4040%42%---
Bessemer Rule of X61%66%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue20%21%24%21%21%
G&A Expenses to Revenue12%12%14%19%12%
R&D Expenses to Revenue18%17%19%18%17%
Opex to Revenue-50%57%58%50%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Wuchan Zhongda Group Co0.1x-5.3x-
Xiamen Xiangyu Co0.1x0.0x4.5x4.4x
SPS Commerce2.6x2.6x8.5x8.0x
HopeRun8.8x8.4x122.2x-
GuoChuang Software7.2x-(97.0x)-
GigaCloud Technology1.1x1.0x8.1x7.9x
New Trend International Logis-Tech1.6x-13.1x-
Infomart4.4x4.2x16.9x16.0x

This data is available for Pro users. Sign up to see all Kinaxis competitors and their valuation data.

Start Free Trial

Kinaxis VC Funding History

Before going public, Kinaxis raised $46M in total equity funding, across 1 round.


Kinaxis Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-14Secondary - publicHarbourVest Partners; TechnoCap$46M--

Acquisitions by Kinaxis

Kinaxis has acquired 4 companies to date.

Last acquisition by Kinaxis was on October 7th 2024. Kinaxis acquired Ono Pharmaceutical for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Kinaxis

Ono Pharmaceutical
MP Objects
Rubikloud
Prana Consulting
Description
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
MP Objects is a Boston-headquartered provider of a SaaS platform for order planning and execution, integrating with ERP, logistics, warehouse, and transportation management systems. The company operates offices in Boston, Rotterdam, Tokyo, and Hyderabad, enabling enterprises to manage micro supply chains for individual orders, boosting revenues and customer experiences while cutting costs and risks. MP Objects serves global manufacturers and retailers seeking to leverage existing software investments for enhanced supply chain visibility.
Rubikloud is a Toronto-based provider of AI platforms for retail optimization. Its cloud-native machine learning tools include Promotion Manager for dynamic pricing and Customer Lifecycle Manager for personalized loyalty campaigns. The company equips multi-billion-dollar retailers operating in North America, Europe, and Asia with forecasting models trained on sales data.
Prana Consulting is a management consulting firm providing strategic advisory services, organizational transformation, and business process optimization to enterprises across healthcare, technology, and financial services sectors, with particular focus on operational excellence, change management, and digital transformation initiatives for mid-market and large corporate clients.
HQ CountryJapanNetherlandsCanadaUnited States
HQ City
-
Rotterdam
Toronto
San Jose, CA
Deal Date7 Oct 202415 Aug 202215 Jun 202026 Feb 2020
Valuationundisclosed$45M$60M$4M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Kinaxis acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Kinaxis

When was Kinaxis founded?Kinaxis was founded in 2013.
Where is Kinaxis headquartered?Kinaxis is headquartered in Canada.
How many employees does Kinaxis have?As of today, Kinaxis has over 1K employees.
Who is the CEO of Kinaxis?Kinaxis' CEO is Robert G. Courteau.
Is Kinaxis publicly listed?Yes, Kinaxis is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Kinaxis?Kinaxis trades under KXS ticker.
When did Kinaxis go public?Kinaxis went public in 2014.
Who are competitors of Kinaxis?Kinaxis main competitors include Wuchan Zhongda Group Co, Xiamen Xiangyu Co, SPS Commerce, HopeRun, GuoChuang Software, GigaCloud Technology, New Trend International Logis-Tech, Infomart, KSEC Intelligent Technooogy, Huitongda Network.
What is the current market cap of Kinaxis?Kinaxis' current market cap is $3B.
What is the current revenue of Kinaxis?Kinaxis' last 12 months revenue is $585M.
What is the current revenue growth of Kinaxis?Kinaxis revenue growth (NTM/LTM) is 14%.
What is the current EV/Revenue multiple of Kinaxis?Current revenue multiple of Kinaxis is 5.3x.
What is the current EBITDA of Kinaxis?Kinaxis' last 12 months EBITDA is $150M.
What is Kinaxis' EBITDA margin?Kinaxis' last 12 months EBITDA margin is 26%.
What is the current EV/EBITDA multiple of Kinaxis?Current EBITDA multiple of Kinaxis is 20.5x.
What is the current FCF of Kinaxis?Kinaxis' last 12 months FCF is $119M.
What is Kinaxis' FCF margin?Kinaxis' last 12 months FCF margin is 20%.
What is the current EV/FCF multiple of Kinaxis?Current FCF multiple of Kinaxis is 25.9x.
How many companies Kinaxis has acquired to date?As of June 2026, Kinaxis has acquired 4 companies.
What was the largest acquisition by Kinaxis?$60M acquisition of Rubikloud on 15th June 2020 was the largest M&A Kinaxis has done to date.
What companies Kinaxis acquired?Kinaxis acquired Rubikloud, MP Objects, Prana Consulting, and Ono Pharmaceutical.
In how many companies Kinaxis has invested to date?Kinaxis hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Kinaxis

Lists including Kinaxis

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial